Aim-To evaluate whether the immunoexpression of c-erbB-2 and p53 is involved in the pathogenesis and progression of salivary tumours with myoepithelial differentiation. Methods-233 tumours from 211 patients were studied. These included 76 primary and 24 recurrent adenocarcinomas (polymorphous low grade adenocarcinoma, 13; epithelial-myoepithelial carcinoma, 19; adenoid cystic carcinoma, 56; and basal cell adenocarcinoma, 12) and 133 pleomorphic adenomas and myoepitheliomas, 96 being primary and the remaining recurrent tumours. All cases were formalin fixed and paraffin wax embedded. A StrepABC peroxidase method and polyclonal c-erbB-2 and p53 specific antisera were used.
c-erbB-2 was not found in any benign or malignant tumour. There was p53 protein accumulation in one primary and one recurrent pleomorphic adenoma and in 10 adenocarcinomas (polymorphous low grade adenocarcinoma, one; epithelialmyoepithelial carcinoma, one; adenoid cystic carcinoma, five; and basal cell adenocarcinoma, three), three of them being recurrences. Conclusions-The c-erbB-2 and p53 proteins are not involved in the pathogenesis of pleomorphic adenoma and myoepithelioma and do not constitute biomarkers in assessing the risk of recurrence. c-erbB-2 is not involved in the genesis of low grade salivary neoplasia with myoepithelial differentiation. The percentage ofthis type of neoplasia with p53 accumulation is low (10%) and does not appear to be related to tumour recurrence. Keywords: p53; c-erbB-2; salivary gland neoplasms p53 is a nuclear phosphoprotein encoded by a gene located on the short arm of chromosome 17 (17pl3.1l) and the c-erbB-2 protein is a growth factor receptor encoded at a different region of the same chromosome (17q1 1.2-12).
Both the overexpression of c-erbB-2 and the accumulation of the p53 protein have been reported in a wide variety of human tumours, including those originating in salivary glands. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, there is some controversy about this issue, and the literature is occasionally conflicting, which justifies further investigations to clarify the involvement of both genes and their products in the tumorigenesis of salivary glands.
It is well known that the majority of benign and malignant salivary gland neoplasms show dual differentiation, with a composite epithelial and myoepithelial phenotype. Our previous studies of malignant mixed tumours'°l demonstrated p53 and c-erbB-2 immunoexpression in high grade carcinomatous areas but not in the benign components, or in the low grade malignant areas, which usually exhibit a modified myoepithelial cell phenotype. These observations suggested that alterations of these protein products are associated with the acquisition of a certain malignant phenotype, supporting the view that low and high grade adenocarcinomatous components of carcinoma ex-pleomorphic adenomas (with and without myoepithelial differentiation, respectively) are related to distinct histogenetic pathways.'0 "
The aim of this study was to confirm these conclusions in salivary gland tumours with similar histology but outside the context of malignant transformation of pleomorphic adenoma. We evaluated p53 and c-erbB-2 immunoexpression in a large series of myoepithelial cell related salivary gland neoplasms, including pleomorphic adenomas, myoepitheliomas, and low grade adenocarcinomas, in an attempt to substantiate our previous results and to evaluate the potential role of the aforementioned proteins in tumour recurrence and progression.
Materials and methods
This study was f~.
: Figure 1 The nuclear staining ofp53 in adenoid cystic carcinoma (original magnification, x333).
been diagnosed by fine needle aspiration ogy. One tumour recurred as a carc ex-pleomorphic adenoma, and this recu was not included in the present study.
In the adenocarcinoma group we an 76 primary neoplasms and 24 recurrence adenocarcinomas were classified as: pol phous low grade adenocarcinoma (n epithelial-myoepithelial carcinoma (n adenoid cystic carcinoma (n = 56), and cell adenocarcinoma (n = 12). Rac therapy had been carried out in nine pa eight with adenoid cystic carcinoma an with epithelial-myoepithelial carcinoma.
Haematoxylin and eosin stained sectii each tumour were re-examined anc representative paraffin block was select the immunohistochemical study. Se (4,m thick) were collected on to g( coated slides, dewaxed in xylene, and drated through ethanol. Endogenous p dase was blocked with 0.3% H20 in met for 10 minutes, at room temperature.
For p53 staining, high temperature a unmasking and incubation with rabbit p( Tissues were considered to be p53 positive when brown stained nuclei were observed in more than 10% of tumour cells. The percentage of p53 positive nuclei was semiquantitatively assessed and scored as > 10% but < 25%, 25-50%, 50-75%, and > 75%. c-erbB-2 immunostaining was considered posi-*.
tive when the neoplastic cells exhibited a distinct cell membrane decoration.
Results

PLEOMORPHIC ADENOMAS AND MYOEPITHELIOMAS
c-erbB-2 immunoexpression was consistently negative in all 133 cases. p53 positivity was obtained in more than 10% of the neoplastic cells in one primary neoplasm and in one recurrent tumour (second recurrence). In the cytol-latter case, both the primary tumour and the inoma first recurrence were negative ( 
Discussion
Frequently, recurrence of pleomorphic adrcinoma; enoma is associated with either incomplete excision of the lesion or tumour capsule disruption during surgical removal. Malignant change occurs in 3-4% of all pleomorphic adenomas" and is associated with longstanding and recurrent tumours. '3 In this study, the immunoexpression of p53 was very low and c-erbB-2 was not immunoexpressed, either in primary or recurrent pleomorphic adenoma, suggesting that these genes are not involved in the pathogenesis of these neoplasms, or in their potential for recurrence. Likewise, they do not seem to constitute biomarkers for the assessment of the risk of their malignant transformation.
These findings support our previous results obtained in the study of a series of carcinoma ex-pleomorphic adenomas" " in which p53 and c-erbB-2 expression was found to be consistently negative in the benign areas of the tumours. In those studies, p53 and c-erbB-2 immunoexpression was found exclusively in the high grade malignant neoplastic components. The present study also shows that malignant salivary gland neoplasms with evidence of myoepithelial lineage do not overexpress c-erbB-2 protein. In fact, none of the 100 adenocarcinomas showed cell membrane staining, which supports the view that this growth factor receptor is not involved in their pathogenesis. This conclusion is in accordance with previous studies2 5 14 performed in cases of salivary gland carcinomas with myoepithelial differentiation but differs from the results obtained by Karja et al.3
In contrast to our observations in this series of low grade adenocarcinomas, the c-erbB-2 protein is expressed overtly by high grade salivary carcinomas, namely salivary duct carcinoma15 1 and high grade mucoepidermoid carcinoma."7 This gives further support to the existence of distinct molecular mechanisms in salivary gland carcinogenesis.
The p53 protein was detected in a small number of low grade salivary adenocarcinomas, irrespective of their histological subtype. The percentage (10%) of positive cases may be overestimated as, in two of the 10 positive tumours, the patients had received radiotherapy. It is known that cell irradiation can induce p53 wild-type protein accumulation'8 and, therefore, may be responsible for false positive results that are not mutation associated.
There is some variation in the literature regarding the frequency of p53 alterations in myoepithelial lineage adenocarcinomas of the salivary glands.5`Distinct methodologies, criteria for positivity, sample types, and subjectivity of the histological classifications are some of the main factors that might explain the disparate results.
To evaluate whether recurrent malignant adenocarcinomas express p53 more frequently than primary neoplasms a large number of lesions was studied by immunohistochemistry. We verified that the percentage of positivity among primary (9.2%) and recurrent (12.5%) tumours did not differ significantly. In a previous study of a small number of cases, Papadaki et al'9 suggested that p53 mutation was involved in tumour recurrence. However, the discrepancy of results could be explained by the sample sizes, distinct methodologies, and assessment criteria. In fact, we considered cases containing more than 10% of p53 stained nuclei as positive, assuming that it would be more likely that occasional positive cells (5 10%) distributed throughout the histological section would be related to stabilisation/ accumulation of the protein, rather than to p53 mutation. Whatever the reasons for the existence of a certain number of p53 positive dispersed cells, in our study, they occurred in 11 primary lesions and only one recurrent lesion, reinforcing the assumption that tumour recurrence is not related to p53 gene alterations.
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